This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / RxSight Class Action Lawsuit Filed
Business class action

RxSight Class Action Lawsuit Filed

Analysis based on 7 articles · First reported Jul 23, 2025 · Last updated Aug 04, 2025

Sentiment
-60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the news of the class action lawsuit against RxSight, as its stock price fell nearly 38%. This event highlights the risks associated with investing in companies that may have overstated product demand or provided misleading financial guidance.

Medical Technology Legal Services
Event Summary

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against RxSight and certain of its top executives, including CEO Ronald Kurtz. The lawsuit, captioned Makaveev v. RxSight, Inc., alleges violations of the Securities Exchange Act of 1934. It claims that RxSight made false and misleading statements, failing to disclose 'adoption challenges' and structural issues that led to declines in sales and utilization, and overstated demand for its light adjustable intraocular lenses (LAL) used in cataract surgery. As a result, RxSight was unlikely to meet its previously issued financial guidance for fiscal year 2025. On July 8, 2025, RxSight reported preliminary Q2 2025 financial results, revealing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue, and subsequently lowered its full year 2025 guidance by approximately $42.5 million. Following this news, RxSight's stock price dropped by nearly 38%. Investors who suffered substantial losses are encouraged to seek appointment as lead plaintiff by September 22, 2025.

Key Actions
100 Robbins Geller Rudman & Dowd LLP announced class action lawsuit RxSight
90 RxSight cut revenue forecast
90 RxSight reported preliminary results
85 Ronald Kurtz disclosed adoption challenges
Entities Involved
stock
RxSight
RxSight is facing a class action lawsuit for allegedly making false and misleading statements regarding its product demand and financial guidance, leading to a significant drop in its stock price.
Importance 100.0 Sentiment -70.0
priv
Robbins Geller Rudman & Dowd LLP
Robbins Geller Rudman & Dowd LLP is the law firm announcing and leading the class action lawsuit against RxSight, representing investors who suffered losses.
Importance 80.0 Sentiment 70.0
per
Ronald Kurtz
Ronald Kurtz, CEO of RxSight, is named as a defendant in the class action lawsuit for allegedly making false and misleading statements.
Importance 70.0 Sentiment -60.0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where RxSight securities are traded.
Importance 10.0 Sentiment 0.0
cnt
United States
Importance 0.0 Sentiment 0.0
Relationships
Robbins Geller Rudman & Dowd LLP related ↔ United States
Nasdaq-100 related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.